The Network Advantage: We can define speed but why can’t we define quality in clinical research?
Join the Association of Multisite Research Corporations (AMRC) for an exclusive webinar unpacking the key findings from our latest whitepaper and industry consultation on quality in multisite clinical research.
AMRC welcomes three new members
The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
Clinical Trials Sector Braces for Wave of M&A
When Headlands Research was acquired by THL Partners earlier this year, the deal sent a clear signal: consolidation in the clinical trials sector is accelerating. Investors are taking a hard look at the potential of site networks and multisite clinical research corporations (MCRCs) to deliver the scale, quality, and efficiency demanded by sponsors, CROs, and patients.
From headwinds to tailwinds: what can we expect for the rest of 2025 in clinical trials?
There’s an ancient Chinese expression that says, “may you live in interesting times.” For the clinical trial industry, the word “interesting” doesn’t even begin to cover the roller-coaster ride of regulatory changes, disappearing grants, and general uncertainty it’s endured over the past six to twelve months.
Member Spotlight: Headlands to be Acquired by THL Partners, Signalling Growing Investor Confidence in the MCRC Model
AMRC founding member Headlands Research has announced its pending acquisition by THL Partners, marking an important moment for both the organization and the broader clinical trials sector. The deal reflects the rapidly rising interest of the investment community in the future of multisite clinical research corporations (MCRCs).
The Network Advantage: A Regulatory Perspective on Clinical Research Innovation
In this informative session, clinical trial professionals will have an opportunity to hear directly from the FDA’s David Burrow on ways industry can advance clinical trial innovation.
Federal News Update: NIH Funding, Vaccine Policy and Looming Drug Pricing Deadline
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
AMRC Launches “Access Granted”
Access Granted is the Association of Multisite Research Corporations’s (AMRC) initiative for increasing site participation at industry events. This month, we are giving away five free tickets to the inaugural Partnerships with Sites Summit, 15 September 2025, Philadelphia by entering our free prize giveaway.
Member spotlight: Javara: How a Mistaken Job Title Led Jennifer Byrne to a Life in Clinical Research
Derailed a bit at first to discover she’d in fact been hired as a clinical researcher, Byrne realized quickly. “I had found my life’s work.” Or, perhaps more accurately, it found her. And over three decades on, she’s CEO of Javara, a founding member of the Association for Multisite Research Corporations (AMRC) and a leading voice in clinical trial innovation.
Identifying the pain points that stop Sponsors and CROs from working with sites
In this candid conversation, representatives from the clinical trial ecosystem will discuss how they can work with sites more effectively. We will use the session to identify key issues and blockers that prevent Sponsors and CROs from engaging with multisite clinical research corporations (MCRCs).
